Association Between Prosthetic Knee Effusions and Phosphodiesterase Type-5 Enzyme Inhibitor Use After Total Knee Arthroplasty: A Case Report.
| Autor: | Anibas JJ; University of Minnesota-Twin Cities, Minneapolis, Minnesota., Brady N; Orthopedic Resident, University of New Mexico School of Medicine, Albuquerque, New Mexico., Cheppalli NS; Assistant Professor, VAMC, Department of Orthopedics and Rehabilitation, University of New Mexico School of Medicine, Albuquerque, New Mexico. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JBJS case connector [JBJS Case Connect] 2023 Feb 10; Vol. 13 (1). Date of Electronic Publication: 2023 Feb 10 (Print Publication: 2023). |
| DOI: | e22.00622 |
| Abstrakt: | Case: Phosphodiesterase type-5 enzyme (PDE5) inhibitors are well tolerated and used to treat erectile dysfunction. We report a case of prosthetic knee effusions associated with PDE5 inhibitor use in a 65-year-old man after total knee arthroplasty (TKA). PDE5 inhibitor treatment was stopped, and the patient had no further episodes of painful effusions. Conclusion: This report describes a previously unknown adverse effect of PDE5 inhibitor use in a prosthetic joint after TKA. We hope to encourage physicians managing patients after joint replacement to be aware of the association between PDE5 inhibitor use and recurrent joint effusions to improve postoperative outcomes. Competing Interests: Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article (http://links.lww.com/JBJSCC/C32). (Copyright © 2023 by The Journal of Bone and Joint Surgery, Incorporated.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|